Skip to content

BRIACELL THERAPEUTICS CORP.: 10-Q filed 2023-06-14

What BRIACELL THERAPEUTICS CORP. reported in its quarterly report filed 2023-06-14 (fiscal Q3 2023): 27 published measures, 79 facts as tagged in accession 0001493152-23-021287.

This filing

Form
10-Q (quarterly report)
Filed
2023-06-14
Fiscal period
fiscal Q3 2023
Accession
0001493152-23-021287 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BRIACELL THERAPEUTICS CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-04-3029,721,868USD
At 2022-07-3142,577,041USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-04-30-5,892,342USD
At 2023-01-31-1,280,586USD
At 2022-07-3110,328,932USD
At 2022-04-309,958,452USD
At 2022-01-3116,425,698USD
At 2021-07-3127,671,721USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-04-3028,170,099USD
At 2022-07-3141,041,652USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-02-01 to 2023-04-30-4,895,436USD89
2022-08-01 to 2023-04-30-17,883,739USD273
2022-02-01 to 2022-04-30-10,015,573USD89
2021-08-01 to 2022-04-30-26,388,551USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-08-01 to 2023-04-30-12,825,853USD273
2021-08-01 to 2022-04-30-9,158,647USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-08-01 to 2023-04-30-45,700USD273
2021-08-01 to 2022-04-30-3,582,874USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-04-30-78,233,576USD
At 2022-07-31-60,349,837USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-02-01 to 2023-04-3015,518,072shares89
2022-08-01 to 2023-04-3015,518,036shares273
2022-02-01 to 2022-04-3015,358,947shares89
2021-08-01 to 2022-04-3015,486,028shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-02-01 to 2023-04-3015,518,072shares89
2022-08-01 to 2023-04-3015,518,036shares273
2022-02-01 to 2022-04-3015,358,947shares89
2021-08-01 to 2022-04-3015,486,028shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-02-01 to 2023-04-30-0.32USD/shares89
2022-08-01 to 2023-04-30-1.15USD/shares273
2022-02-01 to 2022-04-30-0.65USD/shares89
2021-08-01 to 2022-04-30-1.7USD/shares273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-02-01 to 2023-04-30281,189USD89
2022-08-01 to 2023-04-301,659,974USD273
2022-02-01 to 2022-04-30863,627USD89
2021-08-01 to 2022-04-302,196,637USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-02-01 to 2023-04-30-5,677,029USD89
2022-08-01 to 2023-04-30-15,566,503USD273
2022-02-01 to 2022-04-30-4,123,260USD89
2021-08-01 to 2022-04-30-10,054,878USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-04-3029,502,980USD
At 2022-07-3142,346,700USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2021-08-01 to 2022-04-30979USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-04-301,383,094USD
At 2022-07-31941,087USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-04-30218,886USD
At 2022-07-31230,339USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-04-3014,896USD
At 2022-07-3124,103USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-02-01 to 2023-04-305,677,029USD89
2022-08-01 to 2023-04-3015,566,503USD273
2022-02-01 to 2022-04-304,123,260USD89
2021-08-01 to 2022-04-3010,054,878USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-02-01 to 2023-04-303,860,568USD89
2022-08-01 to 2023-04-3010,169,140USD273
2022-02-01 to 2022-04-302,268,805USD89
2021-08-01 to 2022-04-304,852,620USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-04-3015,518,318shares
At 2022-07-3115,269,853shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-04-30-138,684USD
At 2022-07-31-138,684USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2023-02-01 to 2023-04-30-4,895,436USD89
2022-08-01 to 2023-04-30-17,883,739USD273
2022-02-01 to 2022-04-30-10,015,573USD89
2021-08-01 to 2022-04-30-26,388,551USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-02-01 to 2023-04-301,816,461USD89
2022-08-01 to 2023-04-305,397,363USD273
2022-02-01 to 2022-04-301,854,455USD89
2021-08-01 to 2022-04-305,202,258USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2022-08-01 to 2023-04-3011,453USD273
2021-08-01 to 2022-04-3011,453USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-02-01 to 2023-04-30781,593USD89
2022-08-01 to 2023-04-30-2,317,236USD273
2022-02-01 to 2022-04-30-5,892,313USD89
2021-08-01 to 2022-04-30-16,333,673USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2022-08-01 to 2023-04-30-9,207USD273
2021-08-01 to 2022-04-301,958USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-08-01 to 2023-04-30531,972USD273
2021-08-01 to 2022-04-306,945USD273

Inspect the source

Entity
BRIACELL THERAPEUTICS CORP. / CIK 0001610820
Captured
2026-09-20T09:26:46.138Z
SEC response SHA-256
9b120e952e46202c087d84b15420884d11dabee9617ee209952acee5219f65e1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001610820.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))